Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
暂无分享，去创建一个
H. Dombret | S. Chevret | B. Quesnel | C. Preudhomme | P. Fenaux | C. Gardin | S. de Botton | X. Thomas | N. Boissel | Aline Renneville | C. Terré | E. Raffoux | C. Pautas | D. Bordessoule | P. Turlure | T. de Revel | S. Castaigne | N. Gachard | K. Celli-Lebras